Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bionomy Health vs NuuVim

Bionomy Health
Graded #182

Lower grade

vs+1.6000000000000085
NuuVim
Graded #153

Higher grade

The verdict

NuuVim takes it — 68.2/100 to 66.6/100, but only just.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound. Bionomy Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +41
47
88
Dose & formulationNuuVim +21
75
96
Clinical oversightBionomy Health +36
78
42
Labs & monitoringBionomy Health +12
62
50
FulfillmentBionomy Health +28
89
61
Contract termsBionomy Health +6
53
47
Bionomy Health · left barNuuVim · right bar

The numbers

MetricBionomy HealthNuuVim
WeighScore66.6/10068.2/100
GradeCC
Scorecard rank#182#153
Semaglutide$189/mo (starting dose, compounded)$79/mo (all doses, 3-mo plan, new patients only, compounded)
Tirzepatide$249/mo (compounded)$133/mo (all doses, 3-mo plan, new patients only, compounded)
Coverage48 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Bionomy Health

Graded #182 · C

Strengths

  • Cancellation is genuinely unconditional: no subscription, no card on file, no auto-renewal, no cancellation fee — you pay per refill
  • Prices are published before intake on a dedicated GLP-1 page, and the same figures appear in the site's own llms.txt
  • Available in 48 states

Where it loses points

  • The $189 is a starting rate, not a flat one: the page says 'From', the product card says 'Starter', and doses are titrated every four weeks with no published price for the dose you end up on
  • The homepage says muscle preservation is 'included' while the GLP-1 page sells a Muscle Preserve Pack at $109/mo as a separate line item
  • No FDA-approved pathway and no oral route — the site does not mention Wegovy, Ozempic, Zepbound or Mounjaro at all
  • Not available in Alaska or Hawaii
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
NuuVim

Graded #153 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • There is no month-to-month plan: every rate is billed as one three-month payment
  • The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
  • The site's own llms.txt advertises pricing, FAQ and terms files that all 404
  • No state count is published
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard